Journals / MN Kardiyoloji / 2013 / Cilt: 20 - Sayı: 3

Serum monocyte chemoattractant protein 1 levels in patients with stable coronary artery disease

Stabil koroner arter hastalığında serum monosit kemoatraktan protein 1 seviyeleri

Pages
120–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This finding suggests that MCP-1 in atherosclerotic process may be the reflection of response of the body to the traditional coronary risk factors rather than to be an independent causative risk factor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Monocyte chemoattractant protein 1 (MCP-1) is known to increase during atherosclerotic inflammation and is a predictor of increased mortality and morbidity of cardiovascular diseases.
📊
Key Findings & Data:The aim of the present study was to determine the relationship of MCP- 1 levels with the extent of coronary artery diseases (CAD).
💡
Conclusion & Impact:This finding suggests that MCP-1 in atherosclerotic process may be the reflection of response of the body to the traditional coronary risk factors rather than to be an independent causative risk factor.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Monocyte chemoattractant protein 1 (MCP-1) is known to increase during atherosclerotic inflammation and is a predictor of increased mortality and morbidity of cardiovascular diseases. The aim of the present study was to determine the relationship of MCP- 1 levels with the extent of coronary artery diseases (CAD). Material and Method: Eighty patients (52 males) with a mean age of 60±11 years who underwent elective coronary angiography with suspicion of CAD were consecutively included in the study. Venous blood samples were collected before angiography to measure MCP-1 levels. Age, gender, and atherosclerosis risk factors of patients were evaluated. On coronary angiography, a stenosis of over 50% was considered as severe CAD. The extent of CAD was determined by number of severely stenosed vessels. The serum MCP-1 levels were compared with the extent of CAD. Results: The mean serum MCP-1 level was higher in patients with coronary lesions compared to patients with NCA (Normal coronary arteries) (194±40 pg/ml vs. 164±35 pg/ml, p=0.003). The level of MCP-1 was shown to increase with the number of coronary arteries (NCA: 164±35 pg/ml, Non-critical plagues; 184±33 pg/ml, 1-vessel: 198±39 pg/ml, 2-vessel: 183±43 pg/ml and 3-vessel: 219±47 pg/ml, p=0.004). However, in multivariate regression analysis, MCP-1 level was not independently associated with presence of CAD. Conclusion: The levels of MCP-1 were related to number of involved coronary arteries. However, this relationship was not independ- ent of conventional coronary risk factors. This finding suggests that MCP-1 in atherosclerotic process may be the reflection of response of the body to the traditional coronary risk factors rather than to be an independent causative risk factor.

Özet

Amaç: Monosit kemoatraktan protein 1 (MCP-1) aterosklerozun enflamasyonunda artan ve plazmadaki düzeyinin artışı ile kardiyovasküler hastalıkların morbidite ve mortalite artışını göstermede öngördürücüdür. Bu araştırmada, koroner arter hastalığının (KAH) yaygınlığı ile MCP-1 düzeyi arasındaki ilişki araştırıldı. Gereç ve Yöntem: Çalışmaya, KAH şüphesiyle elektif koroner anjiyografi (KAG) yapılan, yaş ortalamaları 60±11 yıl olan, 52 erkek, toplam 80 hasta alındı. KAG öncesi, MCP-1 seviyeleri ölçümü için venöz kan örnekleri alındı. Hastaların yaş, cinsiyet ve ateroskleroz risk faktörleri sorgulandı. KAG’de %50’den fazla darlık ciddi KAH olarak kabul edildi. KAH yaygınlığı, ciddi derecede daralmış damar sayısı ile belirlendi. Serum MCP-1 düzeyleri, KAH yaygınlığı ile karşılaştırıldı. Bulgular: Ortalama MCP-1 seviyeleri, koroner lezyonları olan hastalarda, normal koroner arter hastalarına (NKA) göre daha yüksekti (194±40 pg/ml ; 164±35 pg/ml, p=0.003). MCP-1 seviyeleri, tutulan koroner arter sayısı ile artış görüldü (NKA: 164±35 pg/ml, kritik olmayan plaklar; 184±33 pg/ml, 1-damar: 198±39 pg/ml, 2- damar: 183±43 pg/ml ve 3- damar: 219±47 pg/ml, p=0,004). Bununla birlikte, çok değişkenli regresyon analizinde, MCP-1 seviyesi, KAH mevcudiyetiyle bağımsız bir ilişki bulunmadı. Sonuç: MCP-1 düzeyleri, tutulan koroner damar sayısı ile ilişkilidir. Bununla birlikte, bu ilişki geleneksel KAH risk faktörlerinden bağımsızdır. Bu bulgu, MCP-1’in geleneksel KAH risk faktörlerinden bağımsız bir belirteç olarak aterosklerotik süreci yansıttığını göstermektedir.

🔖

Cite This Article

ŞATIROĞLU, Ö., KOCAMAN, S. A., KARADAĞ, Z., UYDU, H. A., DEMİR, A., BOSTAN, M., ATAK, M., ŞAHİN, İ., DOĞAN, S., DURAKOĞLUGİL, M. E., ÇİÇEK, Y., ERDOĞAN, T. (2013). Serum monocyte chemoattractant protein 1 levels in patients with stable coronary artery disease. MN Kardiyoloji, Cilt: 20 - Sayı: 3, 120–124. https://ajindex.com/articles/297381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Ertaş F.S. Koroner Arter Hastalığı. Actual Medicine 2007; 15(9):8-15 2. Helgadottir A, Thorleifsson G, Manolescu A, et al. A com- mon variant on chromosome 9p21 affects the risk of my- ocardial infarction. Science 2007:316;1491-3. 3. Chen Z, Qian Q, Ma G, et al. A common variant on chro- mosome 9p21 affects the risk of early-onset coronary ar- tery disease. Mol Biol Rep 2008:9259-7 4. Hallenbeck JM, Hansson GK, Becker KJ. Immunology of ischemic vascular disease: plaque to attack. Trends Immunol 2005:26;550-6. 5. Chamorro A, Hallenbeck J. The harms and benefits of in- flammatory and immune responses in vascular disease. Stroke 2006:37;291-3. 6. Qian Q, Chen Z, Ma G. et al. Complement factor H Y402H polymorphism, plasma concentration and risk of coro- nary artery disease. Mol Biol Rep 2008:9306-4. 7. Rollins B. MCP-1: a potential regulator of monocyte re- cruitment in inflammatory disease. Mol Med Today 1996:5;198-204. 8. Nelken N, Coughlin S, Gordon D, Wilcox J. MCP-1 in human atheromatous plaques. J Clin Invest 1991:88: 1121-17. 9. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003:107; 690-5. 10. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 poly- morphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarc- tion in the Framingham Heart Study. Circulation 2005; 112;1113-20. 11. de Lemos JA, Morrow DA, Blazing MA, et al. Serial meas- urement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007:50;2117-24. 12. Park HJ, Chang K, Park CS, J et al. Coronary collaterals: The role of MCP-1 during the early phase of acute my- ocardial infarction. International Journal of Cardiology. 2008:130;409-13. 13. Libby P. Molecular bases of the acute coronary syn- dromes. Circulation 1995;91:2844-50. 14. Birdsall HH, Green DM, Trial J, et al. Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation1997;95:684-92. 15. Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cy- tokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999;19:91-104. 16. Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor